Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan
- 10 August 2011
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 153 (3), 288-296
- https://doi.org/10.1016/j.jconrel.2011.05.005
Abstract
No abstract availableThis publication has 75 references indexed in Scilit:
- Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapyProceedings of the National Academy of Sciences of the United States of America, 2009
- Regimen Simplification to Atazanavir‐Ritonavir Alone as Maintenance Antiretroviral Therapy: Final 48‐Week Clinical and Virologic OutcomesThe Journal of Infectious Diseases, 2009
- Low atazanavir concentrations in cerebrospinal fluidAIDS, 2009
- HIV rebounds from latently infected cells, rather than from continuing low-level replicationProceedings of the National Academy of Sciences of the United States of America, 2008
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences of the United States of America, 2008
- Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous SystemArchives of Neurology, 2008
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990